Faculty of Medicine, University of Technical Sciences and Technologies, Bamako, Mali.
Department of Neurology, Gabriel Touré Teaching Hospital, Bamako, Mali.
PLoS One. 2020 Nov 9;15(11):e0241387. doi: 10.1371/journal.pone.0241387. eCollection 2020.
Diabetic polyneuropathy (DPN) with or without neuropathic pain is a frequent complication of diabetes. This work aimed to determine the prevalence of diabetic polyneuropathy, to describe its epidemiological aspects, and to analyze the therapeutic itinerary of patients with DPN.
This was a cross-sectional, descriptive study performed synchronously over six months at two major follow-up sites for patients with diabetes in Mali. DPN was diagnosed based on the Michigan Neuropathy Screening Instrument (MNSI). The neuropathic nature of the pain and the quality of life of patients were evaluated by the DN4 and the ED-5D scale, respectively. We used three (3) different questionnaires to collect data from patients (one at inclusion and another during the follow-up consultation) and from the caregivers of patients with DPN.
We included 252 patients with diabetes, and DPN was found to have a healthcare facility-based prevalence of 69.8% (176/252). The sex ratio was approximately three females for every male patient. The patients were mostly 31 to 60 years of age, 83% had type 2 diabetes, and 86.9% had neuropathic pain Approximately half of the patients (48.3%) had autonomic neuropathy and they reported moderate to intense pain, which was mainly described as a burning sensation. The patients exhibited impaired exteroceptive and proprioceptive sensations in 51.7% of cases. The patients smoked tobacco in 3.4% of cases, while 36.6% of the patients were obese and had dyslipidemia. The caregivers clearly indicated that appropriate medications were not readily accessible or available for their patients with DPN.
The healthcare facility-based prevalence of DPN with or without neuropathic pain was high in our cohort. These inexpensive and easy-to-use tools (MNSI, DN4) can be used to adequately diagnose DPN in the African context. In Mali, screening and early treatment of patients at risk of DPN should allow for a reduction of the burden of the disease, while caregivers need to be adequately trained to manage DPN.
患有或不伴有神经痛的糖尿病多发性神经病(DPN)是糖尿病的常见并发症。本研究旨在确定 DPN 的患病率,描述其流行病学特征,并分析 DPN 患者的治疗情况。
这是一项在马里两个主要的糖尿病患者随访点同步进行的横断面、描述性研究。DPN 根据密歇根神经病变筛查工具(MNSI)进行诊断。通过 DN4 和 ED-5D 量表评估疼痛的神经病变性质和患者的生活质量。我们使用三个(3)不同的问卷从患者(一个在纳入时,另一个在随访咨询时)和 DPN 患者的照顾者收集数据。
我们纳入了 252 名糖尿病患者,发现医疗机构中 DPN 的患病率为 69.8%(176/252)。男女患者比例约为 3 比 1。患者年龄主要在 31 至 60 岁之间,83%为 2 型糖尿病,86.9%有神经痛。大约一半的患者(48.3%)有自主神经病变,他们报告中度至剧烈疼痛,主要表现为烧灼感。51.7%的患者存在外感受性和本体感觉障碍。3.4%的患者吸烟,36.6%的患者肥胖且血脂异常。照顾者明确表示,他们的 DPN 患者无法轻易获得或获得适当的药物。
在我们的队列中,医疗机构中伴有或不伴有神经痛的 DPN 患病率较高。这些廉价且易于使用的工具(MNSI、DN4)可用于在非洲背景下充分诊断 DPN。在马里,对有 DPN 风险的患者进行筛查和早期治疗应能减轻疾病负担,同时需要对照顾者进行充分培训以管理 DPN。